NXTC
Price:
$1.42
Market Cap:
$39.73M
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical...[Read more]
Industry
Biotechnology
IPO Date
2019-05-09
Stock Exchange
NASDAQ
Ticker
NXTC
According to NextCure, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.65. This represents a change of -7.16% compared to the average of -0.70 of the last 4 quarters.
The mean historical PE Ratio of NextCure, Inc. over the last ten years is -8.63. The current -0.65 PE Ratio has changed 653.54% with respect to the historical average. Over the past ten years (40 quarters), NXTC's PE Ratio was at its highest in in the March 2020 quarter at 26.19. The PE Ratio was at its lowest in in the December 2019 quarter at -35.44.
Average
-8.63
Median
-8.76
Minimum
-26.21
Maximum
-0.51
Discovering the peaks and valleys of NextCure, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 199.09%
Maximum Annual PE Ratio = -0.51
Minimum Annual Increase = -76.41%
Minimum Annual PE Ratio = -26.21
Year | PE Ratio | Change |
---|---|---|
2023 | -0.51 | -10.20% |
2022 | -0.56 | -76.41% |
2021 | -2.39 | -73.59% |
2020 | -9.04 | -65.50% |
2019 | -26.21 | 199.09% |
2018 | -8.76 | -32.15% |
The current PE Ratio of NextCure, Inc. (NXTC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.15
5-year avg
-7.74
10-year avg
-8.63
NextCure, Inc.’s PE Ratio is less than CytomX Therapeutics, Inc. (9.19), less than Spero Therapeutics, Inc. (4.06), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Instil Bio, Inc. (-0.78), greater than Assembly Biosciences, Inc. (-2.10), greater than Nuvation Bio Inc. (-1.34), less than Achilles Therapeutics plc (-0.45),
Company | PE Ratio | Market cap |
---|---|---|
9.19 | $93.74M | |
4.06 | $71.07M | |
-0.98 | $8.20M | |
-0.78 | $92.68M | |
-2.10 | $107.81M | |
-1.34 | $692.60M | |
-0.45 | $29.58M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NextCure, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NextCure, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NextCure, Inc.'s PE Ratio?
How is the PE Ratio calculated for NextCure, Inc. (NXTC)?
What is the highest PE Ratio for NextCure, Inc. (NXTC)?
What is the 3-year average PE Ratio for NextCure, Inc. (NXTC)?
What is the 5-year average PE Ratio for NextCure, Inc. (NXTC)?
How does the current PE Ratio for NextCure, Inc. (NXTC) compare to its historical average?